Major depression is a disease characterized by an inability of neuronal systems to show appropriate adaptive plasticity especially under challenging conditions, such as stress. Conversely, pharmacological intervention may normalize such defects through the modulation of factors that might act in concert for the functional recovery of depressed patients, like the neuropeptide VGF, which has previously shown to possess antidepressant like activity. We analyzed VGF mRNA levels in the brain of rodents exposed to stress or treated with antidepressant drugs. In addition, we assessed VGF expression in leukocytes obtained from 25 drug-free depressed patients before and during antidepressant treatment. We found a persistent reduction of VGF expression after exposure to prenatal stress and an upregulation of its levels following chronic treatment with different antidepressant drugs. Moreover, VGF mRNA levels were significantly reduced in drug-free depressed patients, as compared with controls, and were modulated in response to effective antidepressant treatment. Our data provide further support to the role of VGF in mood disorders and suggest that VGF could be a more specific biomarker for treatment responsiveness.
INTRODUCTION
Major depression (MD) is a severe psychiatric disorder with complex and multifactorial etiology originating from the interaction between environmental and genetic factors (Uher, 2008) . According to recent hypotheses, MD may be characterized by an inability of neuronal systems to show appropriate adaptive plasticity especially under challenging conditions such as stress, a key precipitating factor for depression (Pittenger and Duman, 2008) . Preclinical studies have shown that stress causes neuronal atrophy and negatively affects synaptic plasticity, whereas chronic antidepressant treatment may restore such deficits through a series of neuroadaptive mechanisms (Pittenger and Duman, 2008; Calabrese et al, 2009; Castrén et al, 2007; Krishnan and Nestler, 2008) . One of the molecules implicated in MD pathogenesis and potentially involved in the mechanism of antidepressant drugs is the neurotrophin brain-derived-neurotrophic factor (BDNF) (Castrén et al, 2007) , which enhances synaptic plasticity and may lead to an amelioration of neuronal connections that are defective in vulnerable individuals. In this regard, a number of studies has shown that BDNF levels are reduced in depressed patients (Dwivedi et al, 2003; Sen et al, 2008) as well as in animal models of depression (Pittenger and Duman, 2008; Groves, 2007) and that antidepressant treatment is able to increase BDNF expression in specific brain regions (Krishnan and Nestler, 2008; Kozisek et al, 2008; Calabrese et al, 2007) . However, in addition to BDNF, neuronal remodelling is probably associated with the modulation of a wide array of genes that might act in concert for the functional recovery of depressed subjects. An interesting gene is VGF (nonacronymic), which encodes a secreted neuronal peptide precursor, which is subsequently processed by neuroendocrine-specific prohormone convertases into more than 10 different peptides and becomes localized into the endoplasmic reticulum by a secretory leader sequence and it is released in response to depolarization (Levi et al, 2004) . VGF was originally identified as an NGF-responsive gene but its expression is also highly induced by BDNF in vitro and in vivo (Alder et al, 2003) . Interestingly, VGF gene contains a CREB binding site within its promoter, which is critical for BDNF-induced VGF expression (Bozdagi et al, 2008) . Thus CREB could provide a common element for regulating both BDNF and VGF expression. Studies conducted in VGF knock out animals suggested a role for VGF also in energy balance, because it controls hypothalamic and autonomic outflow pathways that regulate peripheral energy expenditure (Hahm et al, 1999) . Furthermore, VGF is an activity-dependent gene, because the blockade of retinal activity results in decreased VGF expression, whereas lesions of the CNS result in upregulation of VGF expression (Snyder et al, 1998) . In addition, VGF is also regulated by paradigms that reflect increases in activity such as learning, long-term potentiation, seizure and synaptogenesis (Snyder et al, 1998; Bozdagi et al, 2008) .
Finally, VGF levels are reduced in animal paradigms of depression (Thakker-Varia et al, 2007) , whereas its expression can be upregulated following ECS or chronic imipramine treatment (Newton et al, 2003; Conti et al, 2007; Altar et al, 2004; Thakker-Varia et al, 2007) , consistent with the antidepressant activity of VGF (Thakker-Varia et al, 2007; Hunsberger et al, 2007) .
In this study, we provide further evidence for a role of VGF in depression and antidepressant response by conducting a series of studies in rodents exposed to stress or treated with antidepressant drugs. In addition, we provide the first evidence that VGF mRNA levels are reduced in leukocytes of drug-free depressed patients, and are modulated in response to effective antidepressant treatment.
MATERIALS AND METHODS

Animal Studies
Rats were individually housed in 40 Â 25 Â 20 cm Plexiglas boxes, with a metal top and sawdust as bedding, and were maintained in an air-conditioned room (temperature 21 T 1-C, relative humidity 60 T 10%) with lights on from 0800 to 2000 hours and with standard pellet chow and tap water freely available.
For the prenatal stress experiment, animals were male offspring of timed-pregnant Sprague-Dawley rats purchased from a commercial breeder (Charles River, Calco, Italy). The pregnant females from gestational day 14 (E14) until delivery as previously described (Fumagalli et al, 2004 were individually placed in transparent plastic and exposed to restrained stress for 45 min, three times a day (0900, 1200 and 1700 hours). Control pregnant females were left undisturbed in their home cages. All animals gave birth at the normal time (during gestational day 22). Molecular analyses were performed on adult control-and prenatally stressed rats (postnatal day 80).
For the pharmacological study, adult (2-3 months old) male Sprague-Dawley rats (Charles River, Calco, Italy) weighing 225-250 g were treated (by gavage) with vehicle (saline solution), duloxetine (10 mg/kg/day), fluoxetine (10 mg/kg/day) or imipramine (10 mg/kg/twice daily) for 21 days and killed by decapitation 24 h after the last administration. The hippocampus and prefrontal cortex were rapidly dissected, frozen on dry ice and stored at À801C for molecular analysis.
All animal handling and experimental procedures were performed in accordance with the EC (EEC Council Directive 86/609 1987), the Italian legislation on animal experimentation (Decreto Legislativo 116/92), and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Human Blood Samples and VGF mRNA Levels Subjects. Twenty-five patients (age: 43.57±9.13, BMI: 23.55 ± 3.14, 18 females 7 males) affected by MD were recruited by the Psychiatry Rehabilitation Unit of the IRCCS Centro S Giovanni di Dio FBF, Brescia, Italy. The inclusion criteria were a diagnosis of MD according to either ICD 10 and DSM IV criteria, age 18-65 years, parents of Caucasoid European Ethnicity. Exclusion criteria were a personal history of bipolar affective disorder, schizophrenia, mood incongruent psychotic symptoms, primary substance abuse or primary organic disease, current or actively seeking pregnancy, current treatment with antidepressants, antipsychotics or mood stabilizers or any regular treatment for a medical condition. Moreover, no patient was on oral contraceptive pill. Upon entering the study, the wash-out period was at least of 2 weeks and subsequently patients were treated with escitalopram over a period of 3 months. During this period all the patients were co-treated with benzodiazepines until the eighth week of escitalopram treatment. The Montgomery-Asberg Depression Scale, MADRS, was administered at baseline (T0) to assess the illness severity and during escitalopram treatment, at T8 (after 8 weeks of treatment) and T12 (after 12 weeks of treatment) to evaluate symptom improvement. The response to treatment was defined as a reduction of 50% of the MADRS score and according to this definition, we classified patients as responders or non responders in relation to the MADRS score reduction value.
Simultaneously to the clinical evaluation, a blood sample collection was performed.
A control group, consisting of 25 subjects (age: 45.68±10.24, BMI: 24.64±2.44, 14 females and 11 males) with a negative anamnesis for any Axis I disorder (confirmed by the MINI interview), a negative family history for psychoses and mood disorders and without any regular treatment for a medical condition was enrolled in the study. No control participant was on oral contraceptive pill.
Venous blood samples for both patients and controls were collected in the morning after an overnight fast (between 0800 hours and 0900 hours) in PaxGene tubes. After blood samples were withdrawn, PaxGene Tubes were stored at À801C until their processing.
The study was approved by the local ethics committee and all subjects enrolled gave their informed consent to the participation.
Quantification of VGF mRNA Levels by Real Time PCR
For animal studies total RNA was isolated from tissue of different brain structures by single-step guanidinium isothiocyanate/phenol extraction using PureZol RNA isolation reagent (Bio-Rad Laboratories S.r.l. Italia) in accordance with the manufacturer's instructions and quantified by spectrophotometric analysis.
For human blood samples RNA isolation was performed using the PAXGene Blood RNA Kit (Qiagen S.p.A., Milan, MI, Italy) according to the manufacturer's protocols. The RNA quantity was assessed by evaluation of the A260/280 and A260/230 ratios using a Nanodrop spectrometer (NanoDrop Technologies, Wilmington, DE, USA) and the RNA quality was determined using an Agilent Bioanalyzer (Agilent Technologies Italia S.p.A. Cernusco sul Naviglio, MI, Italy). Two micrograms of total RNA were then used for cDNA synthesis and for subsequent gene expression analysis in Real Time PCR. In rodents VGF mRNA levels have been normalized on GAPDH, b-actin (VGF forward primer: GCTGAGGACGCAGTGT and VGF reverse primer: AAGAGCTCTCCCTGG; ID probe b-actin: Rn00667869_m1; ID probe GAPDH: Rn99999916_s1), whereas in human leukocytes on the five housekeeping genes GAPDH, b-actin, b2-microglobulin (B2M), cytochrome c-1 (Cyc1) and ATP synthase, H + transporting mitochondrial F1 complex, -subunit (Atp5b) (ID probe VGF: Hs00705044_s1; ID probe B2m: Hs99999907_m1; ID probe Cyc1: Hs00357717_m1; ID probe Atp5b: Hs00969569_m1; ID probe b-actin: Hs99999903_m1 and ID probe GAPDH: Hs00266705_g1).
Data analyses has been performed according to the comparative C t method by the use of Applied Biosystem Real Time software, that automatically determines, using the auto C t determination feature, the optimal baseline and threshold settings.
Statistical Analysis
Univariate analysis of variance was used for comparing the mean values of VGF mRNA levels in drug-free patients vs controls, whereas clinical and biological changes during treatment were analyzed by means of the General Linear Model according to a repeated measures design with time (T0, T8 and T12) as a within-subjects factor. The Pearson's coefficient was used to evaluate bivariate correlations. Statistical comparisons in animals were carried out using one-way analysis of variance (SPSS version 13.0 software package, website: http://www.spss.com).
RESULTS
Modulation of VGF mRNA Levels in Rodents
We found that VGF mRNA levels are significantly reduced in the hippocampus of prenatally stressed animals (À27% p ¼ 0.013, Figure 1 ), an experimental paradigm that, in line with the developmental hypothesis of mood disorders, results in persistent functional alterations leading to heightened susceptibility for cognitive and neuropsychiatric disorders (Fumagalli et al, 2007) 
VGF mRNA Levels in Healthy Subjects and Depressed Patients
We investigated VGF mRNA expression also in human leukocytes to establish a potential relationship between preclinical data and the clinical setting. We found a significant decrease in VGF mRNA levels in drug-free depressed patients (average MADRS scores 21.42±3.17) with respect to their matched controls (PT0 ¼ 0.67±0.46, C ¼ 1.24 ± 0.77, F ¼ 9.02, p ¼ 0.004, Figure 3a) , although no correlation was found between VGF mRNA levels at T0 and the baseline severity of illness (r ¼ À0.09; p ¼ 0.970). No effects of gender, BMI and age on VGF levels were observed in this group of patients (p ¼ 0.438, p ¼ 0.343 and p ¼ 0.512, respectively). Pharmacological treatment with escitalopram improved the depressive symptomatology at T8 and T12 (mean MADRS scores values of 11.23 ± 7.07 and 7.23 ± 5.15, respectively) with a significant decrease in the MADRS scores between T8 and T0 (po0.001) and between T12 and T0 (po0.001) and with a percentage improvement at T12 of 67.71%. Interestingly, escitalopram treatment significantly modulated VGF expression in depressed subjects (po 0.001). In fact, a planned repeated measure analysis indicated that VGF mRNA levels at T8 were not significantly different from those observed at T0 (PT8 ¼ 0.87± 0.75, p ¼ 0.099), but increased significantly at T12, (PT12 ¼ 1.52 ± 1.07, po0.001 vs PT0, Figure 3a ). In the same group of controls and patients we have also analyzed the expression levels of the neurotrophin BDNF and, interestingly, we observed a pattern of modulation similar to VGF. In fact, BDNF mRNA levels were significantly reduced in drug-free depressed patients at the baseline (PT0) as compared with controls and were restored to normal levels following 12 weeks of antidepressant treatment (Cattaneo et al, 2010) . In addition, to extrapolate some indications on the putative interaction between BDNF and VGF, we calculated a Pearson's correlation factor between the changes of the two trophic molecules induced by Figure 1 VGF mRNA levels are reduced following prenatal stress paradigm in rodents. VGF mRNA levels, analyzed by Real Time PCR were significantly reduced in the hippocampus of rats exposed to prenatal stress, as compared with saline-treated rats (À27% p ¼ 0.013, Figure 1 ). The data expressed as mean percentage of the control group (the group that was not exposed to stress or that received vehicle injection), are the mean ± SEM from 6 to 14 independent determinations. *po0.05 vs control group (One-way ANOVA).
VGF modulation in major depression
A Cattaneo et al treatment in each patient and, interestingly, we find a positive association (r ¼ 0.577; p ¼ 0.012).
Although changes in VGF levels (DVGF mRNA levels) observed in the whole sample during escitalopram treatment did not correlate with symptoms improvement (DMADRS score, r ¼ 0.276; p ¼ 0.226), we found that VGF mRNA levels after 12 weeks of escitalopram treatment increased only in patients whose depressive symptoms ameliorated during the course of treatment (PT12 ¼ 1.76 ± 1.02), but not in non responders (PT12 ¼ 0.82 ± 0.32, p ¼ 0.040 vs treatment responders, Figure 3b ). In particular, the percentage increase in VGF levels (DVGF mRNA levels) after 12 weeks of treatment was of 55.36% in responder patients and of 24.17% in non responders (p ¼ 0.006 responders vs non responders).
DISCUSSION
The data of our study show that the expression of VGF is reduced in rodents under a condition that may enhance the susceptibility to depression and it is significantly upregulated after chronic antidepressant treatment. Moreover, we show for the first time that similar changes are also found in depressed subjects who show reduced levels of VGF at baseline, which are normalized in patients who respond to pharmacological therapy.
It is generally accepted that antidepressant drugs may exert their therapeutic efficacy by improving synaptic plasticity, through the modulation of a number of molecules, which may enhance neuronal resilience (Pittenger and Duman, 2008) . Different peptides with trophic properties, including the neurotrophin BDNF (Pittenger and Duman, 2008; Castrén et al, 2007; Groves, 2007; Kozisek et al, 2008; Calabrese et al, 2007) , FGF2 (Turner et al, 2006) and VEGF (Warner-Schmidt and Duman, 2008) , have antidepressant activity and their expression is upregulated by pharmacological treatment.
VGF has only recently been proposed as a neuropeptide that may mediate antidepressant responses (Thakker-Varia et al, 2007; Hunsberger et al, 2007) . Its expression is reduced in depression paradigms, including learned helplessness and Figure 2 VGF mRNA levels are induced by chronic antidepressant treatment in rodents. VGF mRNA levels were increased following chronic treatment with different antidepressant drugs in rat hippocampus (imipramine, + 28% po0.001; fluoxetine, + 20% p ¼ 0.001; duloxetine, + 20% p ¼ 0.005, (a)) and prefrontal cortex (imipramine, + 38% p ¼ 0.014; fluoxetine, + 32% p ¼ 0.036; duloxetine + 28% p ¼ 0. 04, (b) ). The data expressed as mean percentage of the control group (the group that was not exposed to stress or that received vehicle injection), are the mean±SEM from 6 to 14 independent determinations. *po0.05, **po0.001 vs control group (One-way ANOVA). Figure 3 VGF mRNA levels in leukocytes of healthy controls (C) and in depressed patients (P) at three different sample times. VGF mRNA levels were analyzed by Real Time PCR in leukocytes of 25 healthy controls and 25 depressed patients at three different sample times: at baseline (PT0), when patients were drug free for at least 2 weeks, and after 8 (PT8) and 12 (PT12) weeks of escitalopram treatment. VGF mRNA levels were significantly reduced in drugfree depressed patients as compared with controls (PT0 ¼ 0.67 ± 0.71, C ¼ 1.24 ± 0.77, F ¼ 9.02, p ¼ 0.004), and escitalopram treatment reversed VGF deficiency (PT12 ¼ 1.52±1.07, po0.001 vs PT0, (a). In particular, after 8 weeks of treatment VGF levels were not different from those observed at the baseline, conversely, 12 weeks of treatment were able to significantly increase VGF levels but only in patients (n ¼ 20) whose symptoms ameliorated (b). VGF mRNA levels are expressed in arbitrary units (AU) as a Relative Expression Ratio of the target gene in comparison to the geometric mean of reference genes. *po0.05 PT0 vs C, # po0.001 in PT12 vs PT0 in a; *po0.05 in responders vs non responders in b. Thakker-Varia et al, 2007; Hunsberger et al, 2007) . We show that exposure to prenatal stress produces a persistent reduction of VGF in rat hippocampus that in association with decreased expression of other neurotrophic molecules may lead to reduced plasticity and enhanced vulnerability to psychiatric disorders that represent a long-term consequence of exposure to adversities early in life (Fumagalli et al, 2007) . We also show that chronic treatment with different antidepressant drugs is able to upregulate VGF expression, suggesting that the neuropeptide might represent a common target for antidepressant action. These data are in agreement with previous reports showing that chronic imipramine or ECT can increase the level of VGF in the rat hippocampus (Thakker-Varia et al, 2007; Altar et al, 2004) . We have previously shown that BDNF expression was increased in the same animals chronically treated with duloxetine (Calabrese et al, 2007; Molteni et al, 2009 ). As BDNF and VGF genes are characterized by the presence of the same responsive sequence for the transcription factor CREB it is feasible that these trophic molecules may be modulated through similar mechanisms and/or that can reciprocally modulate each other. Interestingly, we report for the first time that VGF may undergo similar changes in peripheral cells from depressed subjects. Although the role of VGF in leukocytes remains to be established, these cells show gene expression profiles similar to neurons, which may reflect what is occurring in the brain (Sullivan et al, 2006) . In addition similar changes occurring in the brain of patients with psychosis or mood disorders have been observed also in leukocytes supporting the usefulness of these cells to investigate the neurobiology of psychiatric diseases. We found that VGF mRNA levels are significantly reduced in the leukocytes of drug-free depressed patients, as compared with controls, although there is no correlation with the baseline severity of illness. Interestingly, 12 weeks of treatment with the SSRI drug escitalopram upregulate VGF expression although only in responder patients, suggesting that changes in the expression of the neuropeptide may be important for the mechanisms associated with drug response. The above evidence share many similarities to what is known about the peripheral modulation of BDNF in depressed subjects (Krishnan and Nestler, 2008) . In this regard, analyzing BDNF expression levels in the same group of controls and patients we have recently found a decrease of BDNF levels in drug-free depressed patients and a progressive increase following escitalopram treatment (Cattaneo et al, 2010) . Interestingly, we found a positive correlation between the changes occurring in the expression of BDNF and VGF after antidepressant treatment suggesting that the two molecules could be involved in the same mechanisms induced by antidepressants and/or that they might co-operate in determining the functional recovery of patients.
VGF modulation in major depression
Interestingly, whereas symptom improvement was already observed after 8 weeks of treatment, the increase of BDNF or VGF was observed only after 12 weeks of treatment. This suggests that there might be a delay between clinical improvement and 'normalization' of neuroplastic defects. Alternatively, it is worth noticing that all patients were co-treated with benzodiazepines but only up to the eighth week. Hence, treatment with benzodiazepines for a short period does not interfere with clinical antidepressant effects, but might limit or prevent the occurrence of neuroplastic changes, such as the modulation of BDNF and VGF. In accordance with this possibility it has been recently shown that benzodiazepines might interfere with the effects of fluoxetine on adult neurogenesis in rodents (Wu and Castrén, 2009; Gass and Henn, 2009) .
Although further studies on a larger cohort of patients will be required to confirm the present results, we suggest that VGF could be a more specific biomarker associated with the treatment responsiveness as its expression is increased only in treatment responders, whereas BDNF levels were enhanced by pharmacological treatment independently from clinical amelioration (Krishnan and Nestler, 2008; Brunoni et al, 2008) . Serum and plasma BDNF levels can also be reduced in other diseases (Sen et al, 2008) detracting from its use as a diagnostic marker, despite the fact that such changes may be suggestive of common pathophysiological mechanisms. It will be interesting to establish if the changes of VGF can be disease specific or, alternatively, if the combined analysis of different neuropeptides would prove useful for diagnostic purposes as well as to establish treatment responsiveness. In this regard, it has to be noticed that VGF levels have been found altered also in patients with amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (Selle et al, 2005; Pasinetti et al, 2006; Zhao et al, 2008) . Under these conditions it has been proposed that changes in VGF expression may promote neurodegeneration, through NMDA-and AMPA-mediated exitotoxic injury. Neurodegeneration is also a feature of MD, because a reduced hippocampal volume accompanied by neuronal atrophy and cell death has been found in depressed patients and dysfunction of the glutamatergic system has been proposed (Sanacora, 2009 ). Hence, it is possible that a reduction of VGF may represent a common pathophysiological mechanism shared by several disease processes.
The interesting and intriguing finding of our work is that VGF levels increase following AD treatment suggesting an amelioration of neuroplastic processes and more importantly, we observed an increase of VGF only in patients who responded to antidepressant medication suggesting that the trophic molecule may represent a biomarker of treatment outcome. Therefore, it will be interesting to analyze VGF levels during the treatment also in ALS and Alzheimer disease because it should help to monitor the progression of the illness and it should help to clarify and delineate putative functional and therapeutic implication of VGF.
